EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment

Magnus Ingelman-Sundberg iD, Munir Pirmohamed

Journal of Internal Medicine · 2024

DOI: 10.1111/joim.13772 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Internal Medicine, 2024. Verfasst von Magnus Ingelman-Sundberg und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Section of Pharmacogenetics, Biomedicum 5B, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Precision Medicine, Cardiovascular Diseases. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Research Council, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacogenomics is the examination of how genetic variation influences drug metabolism and response, in terms of both efficacy and safety. In cardiovascular disease, patient‐specific diplotypes determine phenotypes, thereby influencing the efficacy and safety of drug treatments, including statins, antiarrhythmics, anticoagulants and antiplatelets. Notably, polymorphisms in key genes, such as CYP2C9, CYP2C19, VKORC1 and SLCO1B1 , significantly impact the outcomes of treatment with clopidogrel, warfarin and simvastatin. Furthermore, the CYP2C19 polymorphism influences the pharmacokinetics and safety of the novel hypertrophic cardiomyopathy inhibitor, mavacamten. In this review, we critically assess the clinical application of pharmacogenomics in cardiovascular disease and delineate present and future utilization of pharmacogenomics. This includes insights into identifying missing heritability, the integration of whole genome sequencing and the application of polygenic risk scores to enhance the precision of personalized drug therapy. Our discussion encompasses health economic analyses that underscore the cost benefits associated with pre‐emptive genotyping for warfarin and clopidogrel treatments, albeit acknowledging the need for further research in this area. In summary, we contend that cardiovascular pharmacogenomic analyses are underpinned by a wealth of evidence, and implementation is already occurring for some of these gene–drug pairs, but as with any area of medicine, we need to continually gather more information to optimize the use of pharmacogenomics in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineCardiovascular DiseasesHumansWarfarinPharmacogenomic TestingClopidogrelCytochrome P-450 CYP2C19AnticoagulantsPharmacogeneticsLiver-Specific Organic Anion Transporter 1Vitamin K Epoxide Reductases

Stichwörter der Autor:innen

CYP2C19SLCO1B1VKORC1clopidogrelpharmacogenomicsstatins

Substanzen

WarfarinClopidogrelCytochrome P-450 CYP2C19AnticoagulantsSLCO1B1 protein, humanLiver-Specific Organic Anion Transporter 1VKORC1 protein, humanVitamin K Epoxide Reductases

Autor:innen und Institutionen

  • Department of Physiology and Pharmacology, Section of Pharmacogenetics, Biomedicum 5B, Karolinska Institutet, Stockholm, Sweden.
  • Wolfson Centre for Personalised Medicine, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.

ORCID-Profile: Magnus Ingelman-Sundberg

Förderung

  • European Research Council
  • Medical Research Council

Zitieren

APA

Ingelman-Sundberg, M., & Pirmohamed, M. (2024). Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment. Journal of Internal Medicine. https://doi.org/10.1111/joim.13772

Vancouver

Ingelman-Sundberg M, Pirmohamed M. Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment. Journal of Internal Medicine. 2024. doi:10.1111/joim.13772

BibTeX
@article{IngelmanSundberg2024,
  author = {Ingelman-Sundberg, Magnus and Pirmohamed, Munir},
  title = {Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment},
  journal = {Journal of Internal Medicine},
  year = {2024},
  doi = {10.1111/joim.13772}
}
Kostenlos starten →